SCHEMBL12875802

SCHEMBL12875802

Cc1cc(F)cc(-c2csc(Cn3cc(C(=O)O)cn3)n2)c1

nearest known ligand 0.39

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
L3MBTL1 Q9Y468 3/20 0.39
RAB9A P51151 4/20 0.37
ALDH1A1 P00352 3/20 0.37
KDM4E B2RXH2 4/20 0.37
POLB P06746 1/20 0.37
GAA P10253 1/20 0.37
HTT P42858 1/20 0.37
AKT1 P31749 1/20 0.36
NPC1 O15118 1/20 0.36
CASP3 P42574 1/20 0.36
SENP8 Q96LD8 1/20 0.36
SENP7 Q9BQF6 1/20 0.36
SENP6 Q9GZR1 1/20 0.36
SIRT5 Q9NXA8 2/20 0.35
HPGD P15428 2/20 0.35
ALKBH1 Q13686 1/20 0.35
CYP1A2 P05177 2/20 0.35
CYP2C19 P33261 2/20 0.35
KLKB1 P03952 2/20 0.35
MEN1 O00255 1/20 0.35

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL12875801 0.88 GRM2 (0.45) L3MBTL1RAB9AALDH1A1KDM4EPOLB
SCHEMBL12875895 0.88 L3MBTL1 (0.39) L3MBTL1RAB9AALDH1A1KDM4EPOLB
SCHEMBL12875908 0.88 L3MBTL1 (0.39) L3MBTL1RAB9AALDH1A1KDM4EPOLB
SCHEMBL12875728 0.87 ALDH1A1 (0.41) L3MBTL1RAB9AALDH1A1KDM4EPOLB
SCHEMBL12875968 0.87 L3MBTL1 (0.41) L3MBTL1RAB9AALDH1A1KDM4EPOLB
SCHEMBL1199036 0.86 MEN1 (0.42) L3MBTL1RAB9AALDH1A1KDM4ENPC1
SCHEMBL12876017 0.86 MEN1 (0.41) L3MBTL1RAB9AALDH1A1KDM4EPOLB
SCHEMBL12875918 0.85 SIRT5 (0.40) L3MBTL1RAB9AALDH1A1KDM4EPOLB
SCHEMBL12876399 0.85 RAB9A (0.53) L3MBTL1RAB9AALDH1A1KDM4EPOLB
SCHEMBL1198867 0.85 RAB9A (0.47) L3MBTL1RAB9AALDH1A1KDM4EPOLB

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-8461348-B2 Heterocyclic derivative and use thereof TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) 2013-06-11 US disclosed
US-20110028493-A1 HETEROCYCLIC DERIVATIVE AND USE THEREOF TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) 2011-02-03 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20110028493-A1 HETEROCYCLIC DERIVATIVE AND USE THEREOF PDE3B, PDE5A, PDE2A L3MBTL1 4726/4885RAB9A 2507/4885ALDH1A1 1037/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.